tbuckley/cabot-search huggingface dataset:
LBA14 De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab+ET in early HR+/HER2+ breast cancer (BC): ADAPT-TP survival results
Authors: N. Harbeck, U. Nitz, M. Christgen, S. Kuemmel, M. Braun, C. Schumacher, J. Potenberg, J. Tio, B. Aktas, W. Malter, H. Forstbauer, R. von Schumann, M. Just, K. Jóźwiak, M. Hauptmann, R. Kates, M. Gräser, R. Wuerstlein, H. Kreipe
Journal: Annals of Oncology (2020)
1623MO Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study
Authors: F. Janku, P. Chi, M. Heinrich, M. von Mehren, R.L. Jones, K. Ganjoo, J. Trent, H. Gelderblom, A. Abdul Razak, M. Gordon, N. Somaiah, J. Jennings, K. Shi, R. Ruiz-Soto, S. George
Journal: Annals of Oncology (2020)
287P Efficacy, safety and pharmacokinetics of a proposed trastuzumab biosimilar HLX02 compared with trastuzumab in metastatic breast cancer: A global phase III study
Authors: Q. Zhang, B. Xu, T. Sun, W. Li, Y. Teng, X. Hu, I. Bondarenko, H. Adamchuk, Y. Li, B. Shan, S. Liu, W. Jiang, X. Zhang, A. Luk, K. Chai
Journal: Annals of Oncology (2020)
Conferring receptors on recipient cells with extracellular vesicles for targeted drug delivery
Authors: Zachary Quinn, Wenjun Mao, Yiqiu Xia, Rhea John, Yuan Wan
Journal: Bioactive Materials (2020)

Triple negative breast cancer (TNBC) is a heterogeneous subset of breast cancer characterized by its lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2), which altogether prevents TNBC from being treated effectively. For many years, the treatment paradigms and overall survival of patients with TNBC have remained largely stagnant. Recent attempts to convert cold tumors to hot tumors by promoting antigen presentation have shown increased T cell infiltration and significantly induced immune responses for tumor killing. Inspired by this concept, the expression of specific targetable antigens on TNBC cells may further benefit relevant targeted drug delivery. In this study, we successfully conferred sufficient HER2 on the surface of TNBC MDA-MB-231 cells via simple EV-plasma membrane fusion with HER2+ extracellular vesicles (EV) derived from HER2 overexpressing BT-474 cells. Subsequently, anti-HER2 antibody conjugated paclitaxel-loaded liposomes were used for HER2-targeted drug delivery. Our findings demonstrated this HER2 grafting, in conjunction with targeted drug delivery, can improve the treatment efficacy
Abstract 15949: Risk of Stroke and Major Bleeding for Dabigatran, Rivaroxaban, and Warfarin Compared to Apixaban Among Non-Valvular Atrial Fibrillation Patients in the United States Medicare Population
Authors: Alpesh Amin, Allison Keshishian, Jeffrey Trocio, Oluwaseyi Dina, Hannah Le, Lisa Rosenblatt, Xianchen Liu, Jack Mardekian, Qisu Zhang, Onur Baser, Lien Vo
Journal: Circulation (2017)

Introduction: Clinical trials have shown that, compared to warfarin, direct oral anticoagulants (DOACs) are at least as effective for reducing stroke/systemic embolism (SE) and associated with simi...
LBA42 POD1UM-202: Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy
Authors: S. Rao, J. Capdevila, D. Gilbert, S. Kim, L. Dahan, T. Kayyal, M. Fakih, A. Demols, L.H. Jensen, K-L.G. Spindler, D. Arnold, S. Tamberi, M.G. Guren, M. Cornfeld, M. Jones, C. Tian, M. Catlett, J-P. Spano
Journal: Annals of Oncology (2020)

Effective salvage treatment for advanced SCAC has not been established; however, checkpoint immunotherapy shows promise. Retifanlimab (INCMGA00012), a humanized IgG4 monoclonal antibody that recognizes human programmed cell death protein 1 (PD-1), has demonstrated activity and tolerability across a broad range of solid tumors. POD1UM-202 was designed to evaluate retifanlimab in pts with previously treated advanced SCAC. Phase II, single-arm study in pts 18 years or older with progression following standard therapy and RECIST measurable disease. Prior immunotherapy was not allowed. Pts with well-controlled human immunodeficiency virus (HIV) infection were eligible. Retifanlimab was administered intravenously at 500 mg every 4 weeks. The primary study endpoint was overall response rate (ORR) assessed by independent central review (ICR) per RECIST v1.1. 94 pts were enrolled with median age of 64 years, most were female (64.9%) and white (76.6%), and had an ECOG PS of 0 (41.5%) or 1 (58.5%). 73.4% had received prior CRT, 17% RT alone, and 97% had received platinum. Liver metastasis was reported in 39 (41.5%) pts and 9 (9.6%) were known to be HIV-positive. Median (range) duration of follow-up was 7 (<1–19) months. ICR confirmed responses were reported in 13 (13.8%) pts (1 complete response; 12 partial responses) and 33 (35.1%) pts had stable disease; median (range) DOR was 9.5 (5.6–not estimable) months. Responses were observed regardless of PD-L1 expression, liver metastases, or HIV-positive status. Median (95% CI) PFS and OS were 2.3 (1.9–3.6) and 10.1 (7.9–NE) months, respectively. Responses were associated with marked prolongation of PFS and OS. Retifanlimab was well-tolerated, including in the HIV-positive population, with a safety profile as expected for a PD-1 inhibitor and a low incidence of treatment discontinuation due to immune-related adverse events (2.1%). Results from this large phase 2 trial demonstrate encouraging efficacy and an acceptable safety profile with retifanlimab in pts with previously treated advanced or metastatic SCAC, including pts with well-controlled HIV infection.
1681P First results of the COCO study: COVID-19 outcomes in patients with cancer
Authors: E. Seguí, M. García de Herreros, E. Auclin, O. Mirallas, D. Casadevall, M. Rodriguez, N. Epaillard, M. Tagliamento, S. Pilotto, R. López-Castro, X. Mielgo, C. Urbano, D. Pesántez, N. Saoudi, M.V. Bluthgen, L. Masfarré, J.N. Minatta, C.A. Cruz, L. Mezquita, A. Prat
Journal: Annals of Oncology (2020)
Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies
Authors: Jia-Wei He, Xu-Jie Zhou, Ji-Cheng Lv, Hong Zhang
Journal: Theranostics (2020)

Infections have been considered to play a critical role in the pathogenesis of IgA nephropathy (IgAN) because synpharyngitic hematuria is a common feature in IgAN. However, how infections participate in this process is still debated. More recent studies have also revealed that the alteration of the gut microbiome exerts a profound effect on host immune responses, contributing to the etiology or progression of autoimmunity. Considering IgA as the first line of defense against bacterial and viral antigens, this review evaluates the relationships among intestinal infections, gut microbiome, and IgA for a better understanding of the pathogenesis of IgAN. Moreover, as a prototype of IgA immunity, we provide detailed clarification of IgAN pathogenesis to shed light on other diseases in which IgA plays a role. Finally, we discuss potential therapies focusing on microbes and mucosal immune responses in IgAN.
NCCN Guidelines Insights: Survivorship, Version 2.2020
Authors: Crystal S. Denlinger, Tara Sanft, Javid J. Moslehi, Linda Overholser, Saro Armenian, K. Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Norah Lynn Henry, Christine Hill-Kayser, Melissa Hudson, Nazanin Khakpour, Divya Koura, Allison L. McDonough, Michelle Melisko, Kathi Mooney, Halle C. F. Moore, Natalie Moryl, Tracey O’Connor, Electra D. Paskett, Chirayu Patel, Lindsay Peterson, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Lillie Shockney, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Phyllis Zee, Nicole R. McMillian, Deborah A. Freedman-Cass
Journal: Journal of the National Comprehensive Cancer Network (2020)

The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for consequences of adult-onset cancer and its treatment, with the goal of helping healthcare professionals who work with survivors, including those in primary care. The guidelines also provide recommendations to help clinicians promote physical activity, weight management, and proper immunizations in survivors and facilitate care coordination to ensure that all of the survivors’ needs are addressed. These NCCN Guidelines Insights summarize additions and changes made to the guidelines in 2020 regarding cardiovascular disease risk assessment and screening for subsequent primary malignancies.
Covid-19: FDA plans strict vaccine approval criteria, angering Trump
Authors: Owen Dyer
Journal: BMJ (2020)

The US Food and Drug Administration (FDA) "will not delay, but will not cut corners" in approving a covid-19 vaccine, its commissioner Stephen Hahn promised a Senate hearing on 23 September, setting up a potential confrontation with President Trump.Any decision will be made by the agency's career scientists, said Hahn, following "the science and data and our rigorous standards.FDA will not permit any pressure from anyone to change that."As Hahn spoke, FDA scientists were informally briefing journalists around Washington to expect tough new standards in the coming days, setting almost as high a bar for vaccine emergency authorisation as demanded by the normal approval process.By requiring phase III trials
126P Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab
Authors: N.I. Nissen, S. Kehlet, M.K. Boisen, M. Liljefors, C. Jensen, A.Z. Johansen, J.S. Johansen, J. Erler, M.A. Karsdal, J. Mortensen, A. Høye, N. Willumsen
Journal: Annals of Oncology (2020)
381P Adult brainstem gliomas: Clinicopathological profile and outcomes of a single center 10-year cohort
Authors: A.N.R. Morais, G.T. Stock, C.C.B.D.L. Zampieri, V.P.D. Camargo, R.C. Bonadio, T.D.A.L. Freddi, A.T.C. Chen, R.C. Ghelfond, O. Feher
Journal: Annals of Oncology (2020)
373MO Delivery and activity of SN-38 by sacituzumab govitecan in CNS tumours
Authors: A.J. Brenner, R. Pandey, J. Chiou, J. Floyd, M. Garcia, P. Surapaneni, V. Kaklamani, K. Lathrop, R. Crownover, J.L. Caron, S. Tiziani
Journal: Annals of Oncology (2020)
A short guide for medical professionals in the era of artificial intelligence
Authors: Bertalan Meskó, Marton Görög
Journal: npj Digital Medicine (2020)

Artificial intelligence (A.I.) is expected to significantly influence the practice of medicine and the delivery of healthcare in the near future. While there are only a handful of practical examples for its medical use with enough evidence, hype and attention around the topic are significant. There are so many papers, conference talks, misleading news headlines and study interpretations that a short and visual guide any medical professional can refer back to in their professional life might be useful. For this, it is critical that physicians understand the basics of the technology so they can see beyond the hype, evaluate A.I.-based studies and clinical validation; as well as acknowledge the limitations and opportunities of A.I. This paper aims to serve as a short, visual and digestible repository of information and details every physician might need to know in the age of A.I. We describe the simple definition of A.I., its levels, its methods, the differences between the methods with medical examples, the potential benefits, dangers, challenges of A.I., as well as attempt to provide a futuristic vision about using it in an everyday medical practice.
606P Novel miRNA-based assay for GEP-NENs management
Authors: M. Bocchini, M. Mazza, G. Simonetti, M. Tazzari, F. Piccinini, S. Ravaioli, F. Foca, M. Tebaldi, F. Nicolini, I. Grassi, S. Severi, G. Paganelli
Journal: Annals of Oncology (2020)
1195P The value of detecting resistance through liquid biopsy
Authors: S. Laurie, J. Agulnik, D. Hao, R. Juergens, D. Ezeife, J. Law, L. Le, L. Kiedrowski, F. Shepherd, V. Cohen, B. Melosky, R. Vandermeer, P. Wheatley-Price, R.B. Lanman, N. Leighl, J. Laskin
Journal: Annals of Oncology (2020)
Rabies vaccination strategies in the Netherlands in 2018: a cost evaluation
Authors: Anita WM Suijkerbuijk, Marie-Josee J Mangen, Manon R Haverkate, Floriana S Luppino, Sabine E Bantjes, Leo G Visser, Corien M Swaan, Wilhelmina LM Ruijs, Eelco AB Over
Journal: Eurosurveillance (2020)

BackgroundThe risk of contracting rabies is low for travellers. However, the number of Dutch travellers potentially exposed abroad following an animal-associated injury and needing post-exposure prophylaxis (PEP) has increased, resulting in increased costs.AimHere, we evaluated the costs and the cost-effectiveness of different pre- and post-exposure interventions in the Netherlands, taking into account the 2018 World Health Organization (WHO) recommendations for the prevention of rabies.MethodsA decision tree-based economic model was constructed. We calculated and compared the cost of different WHO pre-exposure prophylaxis (PrEP) recommendations, intramuscular vs intradermal vaccination and PEP subsequent to increased vaccination coverage in risk groups. We estimated cost-effectiveness, expressed as incremental costs per rabies immunoglobulin (RIG) administration averted, using a societal perspective. Statistical uncertainty regarding number of travellers and vaccination coverage was assessed.ResultsTotal costs at the national level were highest using previous WHO recommendations from 2012, estimated at EUR 15.4 million annually. Intradermal vaccinations in combination with the current recommendations led to the lowest costs, estimated at EUR 10.3 million. Higher vaccination uptake resulted in higher overall costs. The incremental costs per RIG administration averted varied from EUR 21,300-46,800.ConclusionsThe change in rabies PrEP and PEP recommendations in 2018 reduced total costs. Strategies with increased pre-travel vaccination uptake led to fewer RIG administrations and fewer vaccinations after exposure but also to higher total costs. Although larger scale intradermal administration of rabies vaccine can reduce total costs of PrEP and can positively influence vaccination uptake, it remains a costly intervention.
469P Efficacy and safety of anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer - A single-arm, multi-center, phase II study (ALTER-C-002 trial)
Authors: K. Ding, Y. Liu, J. Chen, J. Ying, Q. Xu, D. Xu, L. Sun, Y. Yuan
Journal: Annals of Oncology (2020)
Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice
Authors: Ruixin Sun, Hong Luo, Jingwen Su, Shengmeng Di, Min Zhou, Bizhi Shi, Yansha Sun, Guoxiu Du, Honghong Zhang, Hua Jiang, Zonghai Li
Journal: Molecular Therapy (2020)

A hostile tumor microenvironment is one of the major obstacles for the efficacy of chimeric antigen receptor modified T (CAR-T) cells, and combination treatment might be a potential way to overcome this obstacle. Poly(ADP-ribose) polymerase inhibitor (PARPi) has demonstrated tremendous potential in breast cancer. In this study, we explored the possible combination of the PAPRi olaparib with EGFRvIII-targeted CAR (806-28Z CAR) T cells in immunocompetent mouse models of breast cancer. The results indicated that the administration of olaparib could significantly enhance the efficacy of 806-28Z CAR-T cells in vivo. Interestingly, we observed that olaparib could suppress myeloid-derived suppressor cell (MDSC) migration and promote the survival of CD8+ T cells in tumor tissue. Mechanistically, olaparib was shown to reduce the expression of SDF1α released from cancer-associated fibroblasts (CAFs) and thereby decreased MDSC migration through CXCR4. Taken together, this study demonstrated that olaparib could increase the antitumor activities of CAR-T cell therapy at least partially through inhibiting MDSC migration via the SDF1α/CXCR4 axis. These findings uncover a novel mechanism of PARPi function and provide additional mechanistic rationale for combining PARPi with CAR-T cells for the treatment of breast cancer. A hostile tumor microenvironment is one of the major obstacles for the efficacy of chimeric antigen receptor modified T (CAR-T) cells, and combination treatment might be a potential way to overcome this obstacle. Poly(ADP-ribose) polymerase inhibitor (PARPi) has demonstrated tremendous potential in breast cancer. In this study, we explored the possible combination of the PAPRi olaparib with EGFRvIII-targeted CAR (806-28Z CAR) T cells in immunocompetent mouse models of breast cancer. The results indicated that the administration of olaparib could significantly enhance the efficacy of 806-28Z CAR-T cells in vivo. Interestingly, we observed that olaparib could suppress myeloid-derived suppressor cell (MDSC) migration and promote the survival of CD8+ T cells in tumor tissue. Mechanistically, olaparib was shown to reduce the expression of SDF1α released from cancer-associated fibroblasts (CAFs) and thereby decreased MDSC migration through CXCR4. Taken together, this study demonstrated that olaparib could increase the antitumor activities of CAR-T cell therapy at least partially through inhibiting MDSC migration via the SDF1α/CXCR4 axis. These findings uncover a novel mechanism of PARPi function and provide additional mechanistic rationale for combining PARPi with CAR-T cells for the treatment of breast cancer.
Even Small Pleural Effusion Could Be Potential Pitfall on Posttherapeutic 131I Scintigraphy
Authors: Dong Peng, Fuqiang Shao
Journal: Clinical Nuclear Medicine (2020)

Abstract Pleural and pericardiac effusion could have radioiodine accumulation and be potential pitfall on posttherapeutic 131 I whole-body scintigraphy. However, the volume of the effusion was relatively massive in the previous publications. We report a case of pleural effusion with a very small volume also had radioiodine uptake in a 37-year-old man.
1025MO First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours
Authors: I. Melero, M.F. Sanmamed, E. Calvo, I. Moreno, V. Moreno, T.C. Hernandez Guerrero, M. Martinez-Garcia, A. Rodriguez-Vida, J. Tabernero, A.B. Azaro Pedrazzoli, I. Spanggaard, K.S. Rohrberg, E. Guarin, E. Nueesch, E. Chesne, M. Ceppi, U. Sweere, C. McIntyre, F.S. Lichtenegger, O. Krieter
Journal: Annals of Oncology (2020)
Response to ‘No evidence of SARS‐CoV‐2 infection by polymerase chain reaction or serology in children with pseudo‐chilblain’. Reply from the authors
Authors: D. Caselli, M. Chironna, D. Loconsole, M. Aricò
Journal: British Journal of Dermatology (2020)

Linked Articles: Recalcati et al. Br J Dermatol 2020; 183:1154–1156; Caselli et al. Br J Dermatol 2020; 183:784–785. Colmenero et al. Br J Dermatol 2020; 183:729–737.
1282P Trial-based costs of all-cause adverse events in first-line therapy for advanced non-small cell lung cancer: Findings from CheckMate-227
Authors: S.J. Lubinga, S.B. King, K.A. Betts, S. Rao, F. Castriota, M. Mahin, E. Orvis, S. Marathe, J. Ma, D. Stenehjem
Journal: Annals of Oncology (2020)
Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to &lt; 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study
Authors: M.J. Cork, D. Thaçi, L.F. Eichenfield, P.D. Arkwright, X. Sun, Z. Chen, B. Akinlade, S. Boklage, I. Guillemin, M.P. Kosloski, M.A. Kamal, J.T. O’Malley, N. Patel, N.M.H. Graham, A. Bansal
Journal: British Journal of Dermatology (2020)

Children aged ≥ 6 to < 12 years with severe atopic dermatitis (AD) have limited treatment options. In a 16-week, randomized, placebo-controlled, phase III trial in children, dupilumab, a monoclonal antibody inhibiting interleukin (IL)-4/IL-13 signalling, significantly improved signs and symptoms with acceptable safety; longer-term safety and efficacy data are lacking.To report the pharmacokinetic profile and long-term safety and efficacy of dupilumab in children (aged ≥ 6 to < 12 years) with severe AD.Children (aged ≥ 6 to < 12 years) with severe AD were enrolled in a global, multicentre, phase IIa, open-label, ascending-dose, sequential cohort study and subsequent open-label extension (OLE) study. Patients received single-dose dupilumab 2 or 4 mg kg-1 followed by 8-week pharmacokinetic sampling, then 2 or 4 mg kg-1 weekly for 4 weeks (phase IIa), followed by the same weekly regimen (OLE). Primary endpoints were dupilumab concentration-time profile and treatment-emergent adverse events (TEAEs); secondary assessments included Eczema Area and Severity Index (EASI) and Peak Pruritus Numeric Rating Scale (PP-NRS) score.Of 38 children enrolled, 37 completed phase IIa and 33 continued to the OLE. Nonlinear, target-mediated pharmacokinetics characterized dupilumab concentrations (week 24-48 mean serum concentrations: 2 mg kg-1 , 61-77 mg L-1 ; 4 mg kg-1 , 143-181 mg L-1 ). TEAEs were mostly mild to moderate and transient; none led to treatment discontinuation. The most commonly reported TEAEs were nasopharyngitis (2 mg kg-1 , 47%; 4 mg kg-1 , 56%) and AD exacerbation (29% and 13%, respectively). Single-dose dupilumab rapidly improved AD with further improvements through week 52. Mean EASI and PP-NRS improved by -37%/-33% and -17%/-20% at week 2 (phase IIa) and -92%/-84% and -70%/-58% at week 52 (OLE), respectively.These safety and efficacy results support the use of dupilumab as a continuous long-term treatment for children aged ≥ 6 to < 12 years with severe AD.
1878P Health-related quality of life (HRQoL) assessment for patients with advanced renal cell carcinoma (aRCC) treated with a tyrosine kinase inhibitor (TKI) using electronic patient reported outcomes in daily clinical practice: QUANARIE trial
Authors: G. Mouillet, A. Falcoz, P. Barthélémy, L. Geoffrois, S. Ladoire, J-C. Eymard, J. Plaza, E. Viel, T. Maurina, F. Calcagno, U. Stein, J. Fritzsch, O. Djoumakh, S. Paget-Bailly, A. Thiery-Vuillemin
Journal: Annals of Oncology (2020)
LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
Authors: K. Kato, J-M. Sun, M.A. Shah, P.C. Enzinger, A. Adenis, T. Doi, T. Kojima, J-P. Metges, Z. Li, S-B. Kim, B.C. Chul Cho, W. Mansoor, S-H. Li, P. Sunpaweravong, M.A. Maqueda, E. Goekkurt, Q. Liu, S. Shah, P. Bhagia, L. Shen
Journal: Annals of Oncology (2020)
942P Genomic characterization reveals potential therapeutic targets in nasopharyngeal carcinoma with relapse
Authors: W.C. Cho, K-P. Tse, R.K.C. Ngan, W. Cheuk, V.W. Ma, Y-T. Yang, T. Tang, T.T. Yip, K.T. Tan, S-J. Chen
Journal: Annals of Oncology (2020)
1891P Surgical treatment of bone metastasi: Experience in the General University Hospital of Valencia
Authors: M.M. Franco La Rosa, C. Garcia Gonzalez, A. Blasco Cordellat, V. Zarzuela Sánchez, F.D.A. Aparisi Aparisi, C. Matellanes Palacios, L. Hernandez Ferrando, J. Pastor Peidro, M. Meri Abad, A. Fernandez Diaz, I. Shaheen, M. Nunez Abad, V. Ruiz Cordero, J. Garrido Gallego, L. Sanz Monge, M. Lobo de Mena, A.J. Cunquero Tomas, V. Iranzo, C. Caballero Diaz, C.J.C. Camps Herrero
Journal: Annals of Oncology (2020)
1525O The QOLIXANE trial - Real life QoL and efficacy data in 1st line pancreatic cancer from the prospective platform for outcome, quality of life, and translational research on pancreatic cancer (PARAGON) registry
Authors: T.O. Götze, R.D. Hofheinz, A. Reichart, C. Pauligk, R. Schlag, G.M. Siegler, H-G. Hoeffkes, W. Blau, N. Homann, J. Trojan, O. Waidmann, D. Pink, H. Messmann, V. Kunzmann, A. Vogel, T.J. Ettrich, C. Schönherr, M. Schaaf, G. zur Hausen, S-E. Al-Batran
Journal: Annals of Oncology (2020)